ClinicalTrials.gg
CompletedNCT00499707Updated Mar 21, 2018

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

A Phase 3 interventional study of rosiglitazone maleate/metformin hydrochloride in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 102 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
12th of 51
453 · median 149
Started
2003
with 5 others
Phase 3
21 of 52
none open now
Registered
37th of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2003, is one of 21 in phase 3, and was the 37th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • HbA1c
  • Drug-naive
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years of age
  • Clinical diagnosis of type 2 diabetes
  • >7.5% to 11%
  • FPG \<270mg/dL (15mmol)
  • Current treatment with diet and/or exercise alone, or no more than 15 days of an anti-diabetic medication or insulin within 12 weeks of screening

Exclusion criteria

Exclusion Criteria:

  • renal or hepatic disease
  • Presence of anemia
  • Presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring therapy
  • Systolic blood pressure >170mmHg or diastolic blood pressure >100mmHg, while on anti-hypertensive treatment
  • Chronic disease requiring intermittent or chronic treatment with
  • Any female lactating, pregnant, or planning to become pregnant
  • History of hepatocellular reaction, severe edema or a medically serious fluid related event associated with any thiazolidinedione
  • Presence of acute or chronic metabolic acidosis
  • History of diabetic ketoacidosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
453 participants (actual)

Interventions

  • Drugrosiglitazone maleate/metformin hydrochloride

    Drug pages: Rosiglitazone · Metformin

    rosiglitazone maleate/metformin hydrochloride

06

What researchers measure

Primary outcomes

  1. Change from baseline in hemoglobin A1c (HbA1c) at week 32.

    Time frame: at 32 week

Secondary outcomes

  1. Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks

    Time frame: at 32 weeksInvalid value

07

Study locations

102 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Phoenix, Arizona 85014, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tucson, Arizona 85745, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Los Banos, California 93635, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Jacksonville, Florida 32204, United States
  • GSK Investigational Site
    Melbourne, Florida 32901, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Saint Cloud, Florida 34769, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Fayetteville, Georgia 30214, United States
  • GSK Investigational Site
    Woodstock, Georgia 30189, United States
  • GSK Investigational Site
    Chicago, Illinois 60607, United States
  • GSK Investigational Site
    Evansville, Indiana 47713, United States
  • GSK Investigational Site
    Newburgh, Indiana 47630, United States
  • GSK Investigational Site
    Slidell, Louisiana 70461, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63376, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89103, United States
  • GSK Investigational Site
    Kingston, New York 12401, United States
  • GSK Investigational Site
    New York, New York 10024, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28210, United States
  • GSK Investigational Site
    Mogadore, Ohio 44260, United States
  • GSK Investigational Site
    Downingtown, Pennsylvania 19335, United States
  • GSK Investigational Site
    Warminster, Pennsylvania 18974, United States
  • GSK Investigational Site
    West Chester, Pennsylvania 19382, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Arlington, Texas 76017, United States
  • GSK Investigational Site
    Beaumont, Texas 77701, United States
  • GSK Investigational Site
    Bryan, Texas 77802, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Midland, Texas 79705, United States
  • GSK Investigational Site
    San Antonio, Texas 78221, United States
  • GSK Investigational Site
    San Antonio, Texas 78237, United States
  • GSK Investigational Site
    Seattle, Washington 98108, United States
  • GSK Investigational Site
    Spokane, Washington 99207, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2500, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • GSK Investigational Site
    North Adelaide, South Australia 5006, Australia
  • GSK Investigational Site
    Caulfield, Victoria 3162, Australia
  • GSK Investigational Site
    Fremantle, Western Australia 6959, Australia
  • GSK Investigational Site
    Perth, Western Australia 6000, Australia
  • GSK Investigational Site
    Recife, Pernambuco 50100-130, Brazil
  • GSK Investigational Site
    São Paulo, 04020-041, Brazil
  • GSK Investigational Site
    Calgary, Alberta T3E 0C5, Canada
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3V9, Canada
  • GSK Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 5R3, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 3T1, Canada
  • GSK Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • GSK Investigational Site
    Courtice, Ontario L1E 3C3, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2C 2N9, Canada
  • GSK Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1H 1C2, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9H 5G1, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9J 7B3, Canada
  • GSK Investigational Site
    Renfrew, Ontario K7V 1P6, Canada
  • GSK Investigational Site
    Stoney Creek, Ontario L8G 2V6, Canada
  • GSK Investigational Site
    Toronto, Ontario M3J 1N2, Canada
  • GSK Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • GSK Investigational Site
    Montreal, Quebec H1V 1X4, Canada
  • GSK Investigational Site
    Montreal, Quebec H3S 2W1, Canada
  • GSK Investigational Site
    Montreal, Quebec H4N 2W2, Canada
  • GSK Investigational Site
    Plessisville, Quebec G6L 3J1, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Saint Insidore De Dorchester, Quebec G0S 2S0, Canada
  • GSK Investigational Site
    Saint Marc Des Carrieres, Quebec G0A 4B0, Canada
  • GSK Investigational Site
    Sainte Jerome, Quebec J7Z 5T3, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4S 0A2, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4S 3R8, Canada
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7K 0M5, Canada
  • GSK Investigational Site
    Pusan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Seoul, 139-872, Korea, Republic of
  • GSK Investigational Site
    Uijeongbu,, 480-821, Korea, Republic of
  • GSK Investigational Site
    Tijuana, Baja California Norte 22320, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44340, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64570, Mexico
  • GSK Investigational Site
    Durango, 3400, Mexico
  • GSK Investigational Site
    Mexico, D.F., 11850, Mexico
  • GSK Investigational Site
    Mexico, D.F., 14050, Mexico
  • GSK Investigational Site
    Auckland, 1311, New Zealand
  • GSK Investigational Site
    Auckland, 1701, New Zealand
  • GSK Investigational Site
    Christchurch, 8001, New Zealand

Showing the first 100 of 102 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chou H., et. al.; Rosiglitazone and metformin fixed-dose combination provides superior glycaemic control compared to metformin and rosiglitazone monotherapies, and was well tolerated in drug-naïve patients with T2DM [poster]; European Association for the Study of Diabetes, 10-15 September 2005, Athens, Greece.
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2007
First posted
Jul 11, 2007
Start
Oct 8, 2003
Primary completionActual
Dec 1, 2004
CompletionActual
Dec 16, 2004
Last update
Mar 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00499707
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 11, 2007
Start date
Oct 8, 2003
Primary completion
Dec 1, 2004
Completion
Dec 16, 2004
Last update
Mar 21, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Metformin

Start the discussion